Phase I/II Trial of 5-Fluorouracil and a Noncytotoxic Dose Level of Suramin in Patients with Metastatic Renal Cell Carcinoma
β Scribed by Saby George; Robert Dreicer; Jessie J.L. Au; Tong Shen; Brian I. Rini; Susan Roman; Matthew M. Cooney; Tarek Mekhail; Paul Elson; Guillaume M. Wientjes; Ram Ganapathi; Ronald M. Bukowski
- Book ID
- 119935415
- Publisher
- CIG Media Group, LP.
- Year
- 2008
- Tongue
- English
- Weight
- 134 KB
- Volume
- 6
- Category
- Article
- ISSN
- 1558-7673
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
## RESULTS. Fifty-five patients were enrolled in the trial and 52 were evaluable for ogy, The University of Texas M. D. Anderson response. All patients experienced fever and flu-like symptoms. Grade 3 or 4 nonhe-Cancer Center, Houston, Texas. matologic toxic effects included hypertension (48%), d
## Abstract ## BACKGROUND The objective of this study was to determine the response rate and toxicity of gemcitabine and continuousβinfusion 5βfluorouracil (5βFU) in combination with subcutaneous interleukinβ2 (IL2) and interferonβΞ± (IFNA) in patients with metastatic renal cell carcinoma. ## METH